PYLERA® capsules are a combination antimicrobial product containing bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride for oral administration.
|Description||PYLERA® (bismuth subcitrate potassium, metronidazole, tetracycline HCl) is an effective 3-in-1 capsule for the first line option in the eradication treatment of H. pylori, a bacteria that is now believed to cause up to 90% of duodenal ulcers.|
|Active substance||Bismuth subcitrate potassium 140 mg, metronidazole 125 mg, tetracycline hydrochloride 125 mg given as 3 capsules q.i.d. plus omeprazole for 10 days.|
|Indication||PYLERA® capsules, in combination with omeprazole (20 mg b.i.d), are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori.|
|Regulatory Status||Approved in UAE, Qatar, Bahrain, Kuwait, Lebanon, Tunisia and Morocco|
|Business Partner||Allergan plc|